Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Logo for

Science 325 (5944): 1083-1084

Copyright © 2009 by the American Association for the Advancement of Science

Cell Signaling

Blocking Akt-ivity

David F. Restuccia, and Brian A. Hemmings

Aberrations in cellular signaling pathways that involve the enzyme Akt (also called protein kinase B) are implicated in diverse diseases, including cancer, diabetes, and neurodegenerative disorders (1, 2). Thus, proteins involved in Akt activation and signaling are potential targets for therapeutic intervention. In fact, drugs directed against some of these targets are now in clinical trials for treating cancers, and the inhibition of Akt activation and signaling remains a major goal of drug discovery (3, 4). On page 1134 of this issue, Yang et al. (5) identify a chemical modification of Akt that controls its activation, identifying another potential means to inhibit this kinase in human cancers.

Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH-4058 Basel, Switzerland.

E-mail: hemmings{at}

mda-9/Syntenin Protein Positively Regulates the Activation of Akt Protein by Facilitating Integrin-linked Kinase Adaptor Function during Adhesion to Type I Collagen.
C. Hwangbo, J. Park, and J.-H. Lee (2011)
J. Biol. Chem. 286, 33601-33612
   Abstract »    Full Text »    PDF »
mTOR Complex 2 Targets Akt for Proteasomal Degradation via Phosphorylation at the Hydrophobic Motif.
Y.-T. Wu, W. Ouyang, A. S. Lazorchak, D. Liu, H.-M. Shen, and B. Su (2011)
J. Biol. Chem. 286, 14190-14198
   Abstract »    Full Text »    PDF »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882